A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma

Trial Profile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Defactinib (Primary)
  • Indications Mesothelioma
  • Focus Registrational; Therapeutic Use
  • Acronyms COMMAND
  • Sponsors Verastem
  • Most Recent Events

    • 18 Aug 2016 This trial has been completed in Belgium as per European Clinical Trials Database record.
    • 06 Oct 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 10 Sep 2015 According to a Verastem media release, data from this study will be presented at the 16th World Conference on Lung Cancer (WCLC).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top